Current Rheumatology Reports

, Volume 14, Issue 1, pp 64–70 | Cite as

Laboratory Diagnosis of the Lupus Anticoagulant

ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Abstract

Lupus anticoagulants are autoantibodies that are associated with an increased risk of thromboembolic events and adverse pregnancy outcomes. They are identified by a systematic, laboratory-based approach that includes the following steps: 1) prolongation of a phospholipid-dependent screening assay, 2) demonstration of an inhibitory activity by mixing studies with healthy pooled plasma, and 3) documentation that the inhibitory activity is phospholipid dependent. Laboratory testing can be complicated by several variables, however, including preanalytical factors, multiple reagents and testing platforms, and difficulties with interpreting the results. Guidelines have been developed through several professional organizations that build upon the steps listed above and provide guidance to improve the reproducibility of test results. This article reviews the guidelines developed by the Lupus Anticoagulant/Phospholipid Dependent Antibodies Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis and addresses several common issues encountered during testing for these clinically relevant autoantibodies.

Keywords

Lupus anticoagulant Antiphospholipid antibody Coagulation Laboratory Diagnosis Thrombosis Thromboembolism Antiphospholipid syndrome Hypercoagulable state 

References

  1. 1.
    Conley CL, Hartmann RC. A Hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952;31:621–2.Google Scholar
  2. 2.
    Lee SL, Sanders M. A disorder of blood coagulation in systemic lupus erythematosus. J Clin Invest. 1955;34(12):1814–22.PubMedCrossRefGoogle Scholar
  3. 3.
    Bowie EJ, Thompson Jr JH, Pascuzzi CA, Owen Jr CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med. 1963;62:416–30.PubMedGoogle Scholar
  4. 4.
    Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med. 1980;92(2 Pt 1):156–9.PubMedGoogle Scholar
  5. 5.
    Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GR. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed). 1983;287(6398):1021–3.CrossRefGoogle Scholar
  6. 6.
    Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb. 1972;1:75–95.PubMedGoogle Scholar
  7. 7.
    Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood. 1976;48(4):499–509.PubMedGoogle Scholar
  8. 8.
    Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol. 1961;36:212–9.PubMedGoogle Scholar
  9. 9.
    Rapaport SI, Ames SB, Duvall BJ. A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood. 1960;15:212–27.PubMedGoogle Scholar
  10. 10.
    Margolius Jr A, Jackson DP, Ratnoff OD. Circulating anticoagulants: a study of 40 cases and a review of the literature. Medicine (Baltimore). 1961;40:145–202.Google Scholar
  11. 11.
    Mannucci PM, Canciani MT, Mari D, Meucci P. The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like anticoagulant. Scand J Haematol. 1979;22(5):423–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Adcock DM, Marlar RA. Activated partial thromboplastin time reagent sensitivity to the presence of the lupus anticoagulant. Arch Pathol Lab Med. 1992;116(8):837–40.PubMedGoogle Scholar
  13. 13.
    Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost. 1991;65(3):320–2.PubMedGoogle Scholar
  14. 14.
    Party LAW. Guidelines on testing for the lupus anticoagulant. J Clin Pathol. 1991;44:885–9.CrossRefGoogle Scholar
  15. 15.
    Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74(4):1185–90.PubMedGoogle Scholar
  16. 16.
    Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7(10):1737–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood. 1995;86(2):617–23.PubMedGoogle Scholar
  18. 18.
    Tripodi A, Biasiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem. 2003;49(10):1608–14.PubMedCrossRefGoogle Scholar
  19. 19.
    Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost. 1999;81(6):929–34.PubMedGoogle Scholar
  20. 20.
    Moffat KA, Ledford-Kraemer MR, Plumhoff EA, McKay H, Nichols WL, Meijer P, et al. Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practices. Thromb Haemost. 2009;101(1):178–84.PubMedGoogle Scholar
  21. 21.
    Jennings I, Kitchen S, Kitchen DP, Woods TA, Walker ID. ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories? J Thromb Haemost. 2011;9(10):2117–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost. 1997;77(5):934–7.PubMedGoogle Scholar
  23. 23.
    Teruya J, West AG, Suell MN. Lupus anticoagulant assays: questions answered and to be answered. Arch Pathol Lab Med. 2007;131(6):885–9.PubMedGoogle Scholar
  24. 24.
    Ip BK, Thomson AR, Moriarty HT. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin. Pathology. 2001;33(3):347–52.PubMedGoogle Scholar
  25. 25.
    Liestol S, Wisloff F. Effect of subcutaneous administration of dalteparin on lupus anticoagulant assays. Thromb Res. 2005;115(6):509–17.PubMedCrossRefGoogle Scholar
  26. 26.
    Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res. 2002;107(5):241–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Gosselin RC, King JH, Janatpur KA, Dager WH, Larkin EC, Owings JT. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med. 2004;128(10):1142–5.PubMedGoogle Scholar
  28. 28.
    Tripodi A, Chantarangkul V, Clerici M, Mannucci PM. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost. 2002;88(4):583–6.PubMedGoogle Scholar
  29. 29.
    Olteanu H, Downes KA, Patel J, Praprotnik D, Sarode R. Warfarin does not interfere with lupus anticoagulant detection by dilute Russell's viper venom time. Clin Lab. 2009;55(3–4):138–42.PubMedGoogle Scholar
  30. 30.
    Genzen JR, Miller JL. Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing. Am J Clin Pathol. 2005;124(4):586–93.PubMedCrossRefGoogle Scholar
  31. 31.
    Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115(1):15–20.PubMedCrossRefGoogle Scholar
  32. 32.
    Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011;9(1):133–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost. 2011;105(2):385–6.PubMedCrossRefGoogle Scholar
  34. 34.
    van Os GM, de Laat B, Kamphuisen PW, Meijers JC, de Groot PG. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost. 2011;9(8):1657–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263–71.PubMedCrossRefGoogle Scholar
  36. 36.
    Baca V, Montiel G, Meillon L, Pizzuto J, Catalan T, Juan-Shum L, et al. Diagnosis of lupus anticoagulant in the lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Am J Hematol. 2002;71(3):200–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Bortoli R, Monticielo OA, Chakr RM, Palominos PE, Rohsig LM, Kohem CL, et al. Acquired factor XI inhibitor in systemic lupus erythematosus—case report and literature review. Semin Arthritis Rheum. 2009;39(1):61–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Taher A, Abiad R, Uthman I. Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Lupus. 2003;12(11):854–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.PubMedCrossRefGoogle Scholar
  40. 40.
    Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of HematologyDuke University Medical CenterDurhamUSA

Personalised recommendations